Nanobiotix

Incorporated in 2003, Nanobiotix is a leading, late clinical-stage nanotherapeutics company pioneering new approaches to significantly improve patient outcomes for millions around the world by building new therapies atom by atom. The Nanobiotix philosophy is one rooted in designing pioneer physical-based approaches to bring highly effective and generalized solutions to address high unmet medical needs and challenges. The Nanobiotix global development strategy seeks to address the largest market in oncology—patients who receive radiotherapy as part of their treatment—with NBTXR3 (JNJ-1900). As the first product candidate from the company’s nanoradioenhancer platform, NBTXR3 aims to increase the tumor-killing effect of radiotherapy without increasing damage to surrounding healthy tissues and synergize with other anti-cancer therapies such as immune checkpoint inhibitors. Beyond NBTXR3, the Curadigm Nanoprimer Platform represents the second technology platform from Nanobiotix and the company’s next lever for growth. Curadigm's innovative approach seeks to improve treatment outcomes across several therapeutic classes by optimizing drug bioavailability and efficacy through systemic delivery enhancement. Nanobiotix is listed on the regulated market of Euronext in Paris (Euronext: NANO / ISIN: FR0011341205; Bloomberg: NANO: FP) and on the Nasdaq Global Select Market (Nasdaq: NBTX). The Company’s headquarters are based in Paris, France, with a U.S. affiliate in Cambridge, MA. More: Read our Social Media Community Guidelines: https://nanobiotix.com/social-community-guidelines/